Press Coverage

Duke Cancer Institute will present more than 100 abstracts across multiple cancer types during the ASCO20 Virtual Scientific Program of the 2020 Annual Meeting of the American Society of Clinical Oncology — to be held May 29 to 31. [The ASCO20 Virtual Education Program of the ASCO Annual Meeting will be held August 8 to 10]. Held annually, researchers throughout the world gather for this scientific retreat to share groundbreaking research across multiple cancer types. Over the course of the symposium, attendees will engage in educational sessions, keynote lectures, oral abstract presentations and poster sessions highlighting the latest, breakthrough cancer care.

ASCO 2020

Media Articles

this list will be continuously updated through June

Preview/DCI & Duke at ASCO

On April 29, ASCO announced, in a press release, the top 12 studies to be presented at the cancer science meeting.

Junzo Chino
Junzo Chino, MD

One of the 12 studies — "Changes in cancer mortality rates after the adoption of the Affordable Care Act" (Abstract 2003) — counts  Junzo Chino, MD (a DCI member and radiation oncologist) and Fumiko Chino, MD (a radiation oncologist who joined Memorial Sloan Kettering Cancer Center after completing her residency at DCI last year) among its authors.

Per the study abstract: "This is the first study to show a directly measured cancer survival benefit from the Affordable Care Act on a national scale using a comprehensive database. Hispanic populations appear to have the highest differential cancer mortality benefit after Medicaid expansion. Further study is needed to elucidate why other populations like black patients did not appear to reap the same mortality decrease." The oral presentation of that study will be delivered by study first author Anna Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center.

Landon Brown
Landon Brown, MD

Landon Carter Brown, MD, medical oncology fellow at Duke Cancer Institute will be presented with a Conquer Cancer ASCO Merit Award for his abstract (Abstract 3007) "Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types." He will deliver an oral presentation of his abstract at the annual meeting.

Mentored by Andrew Armstrong, MD, MSc, Brown's research suggests that a subset of patients with LRP1B mutations may be more sensitive to immunotherapy. Per the study abstract conclusions: "This multicenter study shows impressive and durable objective response rates to ICI for patients harboring pathogenic LRP1B alterations when compared to those with LRP1B VUS, independent of TMB/MSI status. Further mechanistic insights and prospective validation studies are warranted."  [Read More]

Other Highlights